DOCSLIB.ORG

Spiolto Respimat

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Spiolto® Respimat® 2.5 micrograms / 2.5 micrograms Solution for Inhalation Tiotropium (as bromide monohydrate) / Olodaterol (as hydrochloride) Consumer Medicine Information What is in this leaflet COPD is a serious lung condition breathing problems or other that can cause difficulty in breathing symptoms of COPD. This leaflet answers some common and constant coughing. The term Ask your doctor if you have any questions about Spiolto Respimat. COPD is associated with the questions about why this medicine conditions chronic bronchitis and It does not contain all the available has been prescribed for you. emphysema. information. Your doctor may have prescribed it Symptoms of COPD include for another reason. It does not take the place of talking to shortness of breath, cough, chest your doctor or pharmacist. This medicine is available only with discomfort and coughing up phlegm. a doctor's prescription. All medicines have risks and Spiolto Respimat contains the active benefits. Your doctor has weighed ingredients, tiotropium (as bromide the risks of you using Spiolto monohydrate) and olodaterol (as Respimat against the benefits they hydrochloride). Tiotropium belongs Before you use expect it will have for you. to a group of medicines called If you have any concerns about anticholinergics. Olodaterol belongs Spiolto Respimat using this medicine, ask your to a group of medicines called long- doctor or pharmacist. acting bronchodilators. These When you must not use it This leaflet was last updated on the medicines are used to relax the Do not use Spiolto Respimat if you date at the end of this leaflet. More breathing tubes or air passages that have an allergy to: carry air to and from the lungs and to recent information may be available. • any medicine containing keep the air passages in the lungs The latest Consumer Medicine tiotropium bromide or olodaterol open and make breathing easier. Information is available from your hydrochloride (the active pharmacist, doctor or from Each dose of Spiolto Respimat will ingredients) www.medsafe.govt.nz/Consumers/ keep your air passages open for 24 • any of the ingredients listed at the cmi/CMIForm.asp and may contain hours. end of this leaflet important information about the Regular use of Spiolto Respimat can medicine and its use of which you • any medicine containing atropine also help when you have ongoing or its derivatives, e.g. ipratropium should be aware. shortness of breath related to your or oxitropium Keep this leaflet with the medicine. disease, and will help minimise the • any other anticholinergic You may need to read it again. effects of the disease on your everyday life. medicines. Spiolto Respimat is for oral Some of the symptoms of an allergic inhalation only. The solution for reaction may include: What Spiolto inhalation is contained in the Spiolto • rash, itching or hives on the skin Respimat cartridge and inhaled using Respimat is used for • swelling of the face, lips, tongue the Spiolto Respimat inhaler supplied or other parts of the body Spiolto Respimat is used for the with the medicine. • shortness of breath, wheezing or treatment of Chronic Obstructive As COPD is a long-term condition, difficulty breathing. Pulmonary Disease, also called you should take Spiolto Respimat COPD. every day even if you do not have Do not give this medicine to a child or adolescent under the age of 18 years. SPIOLTO RESPIMAT NZ CMI V02 1 Safety and effectiveness in children • diabetes glaucoma and migraine such as younger than 18 years have not been • severe liver problems. propranolol (beta-blockers) established. • Tell your doctor if you are medicines used for glaucoma, Do not use Spiolto Respimat to pregnant or plan to become including eye drops such as treat asthma. pregnant or are breast-feeding. timolol Safety and effectiveness in the Your doctor can discuss with you the • medicines used to treat treatment of asthma has not been risks and benefits involved. depression and other mental established. disorders such as tricyclic If you have not told your doctor Do not use Spiolto Respimat to antidepressants or MAO about any of the above, tell inhibitors. relieve an acute attack of him/her before you start using breathlessness or wheezing. Spiolto Respimat. These medicines may be affected by Spiolto Respimat should only be Spiolto Respimat or may affect how Do not allow the mist to enter your well it works. You may need to take used for maintenance treatment of eyes. Should this occur, your COPD. different amounts of your medicines, immediately flush your eyes with or you may need to take different Do not use this medicine after the cold tap water for several minutes, medicines. expiry date printed on the inhaler stop using Spiolto Respimat and label or carton, or if the packaging immediately consult your doctor Your doctor and pharmacist have is torn or shows signs of for further advice. more information on medicines to be careful with or avoid while using this tampering. If the mist enters the eye, it may medicine. If it has expired or is damaged, return result in eye pain or discomfort, it to your pharmacist for disposal. blurred vision, seeing halos around If you are not sure whether you lights or coloured images in should start taking this medicine, association with red eyes (i.e. narrow How to use Spiolto talk to your doctor. angle glaucoma). Eye symptoms may be accompanied by headache, nausea Respimat or vomiting. Before you start to use it Follow all directions given to you Use this medicine only with the Tell your doctor if you have any by your doctor or pharmacist Respimat device. allergies to any other medicines or carefully. any other substances, such as They may differ from the Taking other medicines foods, preservatives or dyes. information contained in this leaflet. Tell your doctor or pharmacist if Tell your doctor if you have, or If you do not understand the you are using any other medicines, have had, any of the following instructions on the box, ask your including any that you get without medical conditions: doctor or pharmacist for help. a prescription from your • asthma (you should not use pharmacy, supermarket or health Spiolto Respimat for the How much to use food shop. treatment of asthma) Take TWO PUFFS, once a day at Some medicines and Spiolto • acute worsening of your the same time of the day. Respimat may interfere with each breathing problems other. These include: You need to take two puffs to get the • heart problems full dose. Two puffs are equal to one • similar medicines used to treat dose. • high blood pressure your breathing problems, including other anticholinergic • seizures How to use it medicines such as ipratropium • overactive thyroid gland Spiolto Respimat is for inhalation (thyrotoxicosis) • medicines that can lower the amount of potassium in your use only. • high pressure in the eye blood. These include medicines Make sure that you know how to (glaucoma) used to treat breathing problems use your Spiolto Respimat inhaler • kidney or liver problems such as theophylline, steroids properly. • problems with passing urine such as prednisolone and The instructions for use are provided diuretics (water tablets) • problems with your prostate at the end of this leaflet. • gland medicines used to treat high Carefully read the instructions for blood pressure, heart conditions, use and follow the diagrams that SPIOLTO RESPIMAT NZ CMI V02 2 show you how to use the Spiolto If you are not sure what to do, ask While you are using Respimat inhaler. your doctor or pharmacist. Spiolto Respimat If you do not understand the If you have trouble remembering instructions on how to use the to take your medicine, ask your Things you must do Spiolto Respimat inhaler, ask your pharmacist for some hints. doctor or pharmacist for help. Stop using Spiolto Respimat and tell your doctor immediately if you Use the Spiolto Respimat inhaler If you use too much get sudden tightness of the chest, supplied in the pack to breathe in (overdose) coughing, wheezing or the solution containing the Immediately telephone your doctor breathlessness immediately after medicine from the Spiolto or the Poisons Information Centre using the Spiolto Respimat. Respimat cartridge. (telephone 0800 764 766) for These may be signs of a condition Insert the Spiolto Respimat advice, or go to Emergency at your called bronchospasm. cartridge into the Spiolto Respimat nearest hospital, if you think that inhaler to prepare the inhaler for you or anyone else may have used If you are about to be started on first use. too much Spiolto Respimat. Do any new medicine, remind your doctor or pharmacist that you are The Spiolto Respimat inhaler this even if there are no signs of using Spiolto Respimat. releases a mist of solution slowly and discomfort or poisoning. gently, making it easy to inhale it You may need urgent medical Tell any other doctors, dentists and into your lungs where it is needed. attention. pharmacists who are treating you The mist containing the medication is Symptoms of an overdose may that you are using this medicine. released by pressing the dose release include: If you become pregnant while button. • high or low blood pressure, using this medicine, tell your dizziness, light-headedness doctor immediately. When to use it If you are a smoker, you should • blurred vision Take your medicine at about the stop smoking. • changes in heart rate (fast, slow same time each day. Your doctor or pharmacist can advise or irregular), palpitations Taking it at the same time each day you on the steps to take to quit will have the best effect. It will also • nervousness or feeling anxious smoking. help you remember when to take it. • inability to sleep Keep all of your doctor's • headache appointments so that your progress How long to use it • shaking or tremors can be checked.
Recommended publications
  • Study Protocol and Statistical Analysis Plan

    Study Protocol and Statistical Analysis Plan

    Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 RANDOMIZED CONTROLLED PILOT STUDY USING PROPRANOLOL TO DECREASE GENE EXPRESSION OF STRESS-MEDIATED BETA- ADRENERGIC PATHWAYS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Version 3.0 Principal Investigator: Jennifer M. Knight, MD Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee, WI 53226 Telephone: 414-955-8908 Fax: 414-955-6285 Email: [email protected] Co-Investigator: J. Douglas Rizzo, MD, MS CIBMTR Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-0700 Fax: 414-805-0714 Email: [email protected] Co-Investigator: Parameswaran Hari, MD, MS Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-4600 Fax: 414-805-4606 Email: [email protected] Consultant Steve W. Cole, PhD and Statistician: UCLA-David Geffen School of Medicine 10833 LeConte Ave 11-934 Factor Bldg Los Angeles, CA 90095-1678 Telephone: 310-267-4243 Email: [email protected] 1 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 Sponsor: Medical College of Wisconsin Funding Sponsor: This project has an offer of sponsorship from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. 2 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 PROTOCOL SYNOPSIS Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients Principal Investigator: Jennifer M. Knight, MD Study Design: This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma.
  • Therapeutic Class Overview Inhaled Anticholinergics

    Therapeutic Class Overview Inhaled Anticholinergics

    Therapeutic Class Overview Inhaled Anticholinergics Therapeutic Class Overview/Summary: The inhaled anticholinergics are a class of bronchodilators primarily used in the management of chronic obstructive pulmonary disease (COPD), a condition characterized by progressive airflow restrictions that are not fully reversible.1-3 Symptoms associated with COPD typically include dyspnea, cough, sputum production, wheezing and chest tightness. Specifically, inhaled anticholinergics work via the inhibition of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation. Meaningful increases in lung function can be achieved with the use of inhaled anticholinergics in patients with COPD.1-3 The available single-entity inhaled anticholinergics include aclidinium (Tudorza® Pressair), glycopyrrolate (Seebri Neohaler®), ipratropium (Atrovent®, Atrovent® HFA), tiotropium (Spiriva®, Spiriva Respimat®) and umeclidinium (Incruse Ellipta®) with the combination products including glycopyrrolate/indacaterol (Utibron Neohaler®), umeclidinium/vilanterol (Anoro Ellipta®), tiotropium/olodaterol (Stiolto Respimat®) and ipratropium/albuterol, formulated as either an inhaler (Combivent Respimat®) or nebulizer solution (DuoNeb).4-15 Ipratropium, a short-acting bronchodilator, has a duration of action of six to eight hours and requires administration four times daily. Aclidinium, glycopyrrolate, tiotropium and umeclidinium are considered long-acting bronchodilators. Aclidinium is dosed twice daily, while glycopyrrolate, tiotropium and umeclidinium
  • Olodaterol Monograph

    Olodaterol Monograph

    Olodaterol Monograph Olodaterol (Striverdi Respimat) National Drug Monograph VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechan Olodaterol is a long-acting beta2-adrenergic agonist (LABA). Binding to and activating ism of Action beta2-adrenoceptors in the airways results in stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3’, 5’ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells. Indication(s) Under Long-term once daily maintenance bronchodilator treatment of airflow obstruction in Review patients with COPD including chronic bronchitis and/or emphysema Dosage Form(s) Inhalation spray for oral inhalation via Respimat (a soft-mist inhaler) Under Review The soft-mist inhalers (SMI) provide multi-dose medication using liquid formulations similar to that used in nebulizers and are propellant-free. Presently, Respimat is the only SMI commercially available for clinical use. The soft mist is released at a slower velocity and has more prolonged spray duration than the mist produced from pressurized metered dose inhalers (pMDIs). Pressurized MDIs require coordination of actuation with inhalation which may be difficult for some patients partly due to the rapid speed at which the drug is delivered and the short duration of the mist.
  • Long-Acting Beta-Agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents

    Long-Acting Beta-Agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents

    UCLA UCLA Previously Published Works Title Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Permalink https://escholarship.org/uc/item/7s74p6sc Journal Respiratory Research, 11(1) ISSN 1465-9921 Authors Tashkin, Donald P Fabbri, Leonardo M Publication Date 2010-10-29 DOI http://dx.doi.org/10.1186/1465-9921-11-149 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Tashkin and Fabbri Respiratory Research 2010, 11:149 http://respiratory-research.com/content/11/1/149 REVIEW Open Access Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Donald P Tashkin1*, Leonardo M Fabbri2 Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting b2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limita- tion, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clini- cally meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated. Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD.
  • Trelegy Ellipta Patient Information

    Trelegy Ellipta Patient Information

    PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PRTRELEGY ELLIPTA fluticasone furoate, umeclidinium, vilanterol dry powder for oral inhalation Read this carefully before you start taking TRELEGY ELLIPTA and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about TRELEGY ELLIPTA. What is TRELEGY ELLIPTA used for? Chronic Obstructive Pulmonary Disease (COPD): TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is used in adults for the long-term treatment of a lung disease called Chronic Obstructive Pulmonary Disease or COPD. This includes chronic bronchitis and emphysema. TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is used in patients who are not adequately treated by other combination medications (ICS/LABA or LAMA/LABA). TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is the only strength indicated for the treatment of COPD. People with COPD are also likely to experience “flare-ups” during which their symptoms become worse. If you have a history of experiencing “flare-ups” TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg can help reduce the symptoms you feel when this happens. If you are a smoker, it is important to quit smoking. This will help decrease the symptoms of COPD and potentially increase your lifespan. Asthma: TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg and 200 mcg/62.5 mcg/25 mcg are used for the long-term treatment of asthma in people aged 18 years and older whose asthma is not well controlled with a maintenance long-acting beta2-agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS).
  • (Lamas) a New Frontier for COPD and Asthma Treatment

    (Lamas) a New Frontier for COPD and Asthma Treatment

    White Paper Long-Acting Muscarinic Agents (LAMAs) A New Frontier for COPD and Asthma Treatment LAMAs in Asthma and COPD Table of Contents 1. Introduction ............................................................................................. 3 2. Tiotropium Bromide ................................................................................. 4 3. Tiotropium + Olodaterol .......................................................................... 7 4. Aclidinium Bromide ................................................................................. 8 5. Aclidinium + Formoterol (ACLIFORM) ....................................................... 9 6. Glycopyrronium Bromide ....................................................................... 10 © 7. Glycopyrronium Bromide + Indacaterol (ULTIBRO )............................... 11 8. Glycopyrronium Bromide + Formoterol .................................................. 13 9. Umeclidinium ........................................................................................ 13 10. Umeclidinium + Vilanterol ..................................................................... 14 11. Triple Therapy ........................................................................................ 16 12. Conclusions ............................................................................................ 16 13. About the Author ................................................................................... 17 14. About CROMSOURCE ............................................................................
  • Once-Daily Long-Acting Beta-Agonists for Chronic Obstructive Pulmonary Disease: an Indirect Comparison of Olodaterol and Indacaterol

    Once-Daily Long-Acting Beta-Agonists for Chronic Obstructive Pulmonary Disease: an Indirect Comparison of Olodaterol and Indacaterol

    International Journal of COPD Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol Neil S Roskell1 Purpose: In the absence of head-to-head clinical trials comparing the once-daily, long-acting Antonio Anzueto2 beta2-agonists olodaterol and indacaterol for the treatment of chronic obstructive pulmonary Alan Hamilton3 disease (COPD), an indirect treatment comparison by systematic review and synthesis of the Bernd Disse4 available clinical evidence was conducted. Karin Becker5 Methods: A systematic literature review of randomized, controlled clinical trials in patients with COPD was performed to evaluate the efficacy and safety of olodaterol and indacaterol. 1Statistics, Bresmed Health Network meta-analysis and adjusted indirect comparison methods were employed to evaluate Solutions Ltd, Sheffield, UK; 2 School of Medicine, University treatment efficacy, using outcomes based on trough forced expiratory volume in 1 second (FEV1), of Texas Health Science Center, Transition Dyspnea Index, St George’s Respiratory Questionnaire total score and response, San Antonio, TX, USA; 3Medical Department, Boehringer Ingelheim rescue medication use, and proportion of patients with exacerbations. (Canada) Ltd, Burlington, ON, Results: Eighteen trials were identified for meta-analysis (eight, olodaterol; ten, indacaterol). 4 Canada; Medical Department, Olodaterol trials included
  • Montelukast and Neuropsychiatric Events in Children with Asthma: a Nested Case-Control Study

    Montelukast and Neuropsychiatric Events in Children with Asthma: a Nested Case-Control Study

    ORIGINAL ARTICLES Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case–Control Study S. Dresden Glockler-Lauf, MPH1, Yaron Finkelstein, MD1,2,3,4,5, Jingqin Zhu, MSc1,2, Laura Y. Feldman, MPH1, and Teresa To, PhD1,2,6 Objective To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. Study design A matched, nested case–control design was used to identify cases and controls from a cohort of children aged 5-18 years with physician-diagnosed asthma from 2004 to 2015, in Ontario, Canada, prescribed an asthma maintenance medication. Cases were children with a hospitalization or emergency department visit for a neuropsychiatric event. Cases were matched to up to 4 controls on birth year, year of asthma diagnosis, and sex. The exposures were dispensed prescriptions for montelukast (yes/no) and number of dispensed montelukast prescriptions in the year before the index date. Conditional logistic regression was used to measure the unadjusted OR and aOR and 95% CIs for montelukast prescription and neuropsychiatric events. Covariates in the adjusted model included sociodemographic factors and measures of asthma severity. Results In total, 898 cases with a neuropsychiatric event and 3497 matched controls were included. Children who experienced a new-onset neuropsychiatric event had nearly 2 times the odds of having been prescribed montelu- kast, compared with controls (OR 1.91, 95% CI 1.15-3.18; P = .01). Most cases presented for anxiety (48.6%) and/ or sleep disturbance (26.1%). Conclusions Children with asthma who experienced a new-onset neuropsychiatric event had nearly twice the odds of having been prescribed montelukast in the year before their event.
  • Pharmacology and Therapeutics of Bronchodilators

    Pharmacology and Therapeutics of Bronchodilators

    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
  • TRELEGY ELLIPTA Safely and Effectively

    TRELEGY ELLIPTA Safely and Effectively

    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypercorticism and adrenal suppression may occur with very high These highlights do not include all the information needed to use dosages or at the regular dosage in susceptible individuals. If such TRELEGY ELLIPTA safely and effectively. See full prescribing changes occur, discontinue TRELEGY ELLIPTA slowly. (5.8) information for TRELEGY ELLIPTA. • If paradoxical bronchospasm occurs, discontinue TRELEGY ELLIPTA and institute alternative therapy. (5.10) TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol • Use with caution in patients with cardiovascular disorders because of inhalation powder), for oral inhalation use beta-adrenergic stimulation. (5.12) Initial U.S. Approval: 2017 • Assess for decrease in bone mineral density initially and periodically --------------------------- RECENT MAJOR CHANGES --------------------------- thereafter. (5.13) Indications and Usage, Maintenance Treatment of Asthma (1.2) 9/2020 • Glaucoma and cataracts may occur with long-term use of ICS. Worsening Dosage and Administration, Recommended Dosage for 9/2020 of narrow-angle glaucoma may occur. Use with caution in patients with Maintenance Treatment of Asthma (2.3) narrow-angle glaucoma and instruct patients to contact a healthcare Contraindications (4) 9/2020 provider immediately if symptoms occur. Consider referral to an Warnings and Precautions, Serious Asthma-Related Events – 9/2020 ophthalmologist in patients who develop ocular symptoms or use Hospitalizations, Intubations, Death (5.1) TRELEGY ELLIPTA long term. (5.14) Warnings and Precautions, Effect on Growth (5.18) 9/2020 • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct --------------------------- INDICATIONS AND USAGE ---------------------------- patients to contact a healthcare provider immediately if symptoms occur.
  • Vocal Cord Dysfunction (VCD) Evaluation

    Vocal Cord Dysfunction (VCD) Evaluation

    Vocal Cord Dysfunction (VCD) Evaluation Scheduling Your Test: Tell the medical staff if you: • Have a history of hives, swelling of the upper airway, or both • Are pregnant (or chance of being pregnant), breastfeeding • Have a heart condition (heart attack/stroke in last 3 months, uncontrolled blood pressure) • Have certain types of blood vessel problems (i.e. aortic or cerebral aneurysm) ❖ Fill out the VCD questionnaire form. ❖ If the patient is <18 yrs. old, a parent/legal guardian should be present for the entire visit. Preparing For Your Test: **Please read carefully & call our office if you have questions. • You may need to stop certain medications prior to the test (see chart below for details). • Continue inhaled steroids at the SAME DOSE. Examples: Aerospan, Alvesco, ArmonAir, Arnuity Ellipta, Asmanex, Flovent, Pulmicort, QVAR • Continue reflux medications such as cimetidine (Tagamet), esomeprazole (Nexium), famotidine (Pepcid), lansoprazole (Prevacid), omeprazole (Prilosec), or ranitidine (Zantac). On the Day of the Visit: • Wear comfortable clothing and athletic shoes. • Do not wear lipstick, perfume, or cologne. • NO smoking, coffee, cola/caffeinated beverages, or chocolate. • Do not exercise at least 6 hrs prior to your test. • Avoid large meals within 2 hours before the test. • Tell your provider if you have had a cold in the last 4 wks. Why is this Evaluation Being Ordered? Your doctor is concerned that some of your symptoms may indicate that you might have vocal cord dysfunction (VCD). This condition can often mimic asthma. Instead of opening during breathing, the vocal cords abnormally close in VCD, causing throat tightness and shortness of breath.
  • Fluticasone Furoate, Umeclidinium and Vilanterol (Trelegy)

    Fluticasone Furoate, Umeclidinium and Vilanterol (Trelegy)

    pat hways Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 Key points The content of this evidence summary was up-to-date in June 2018. See summaries of product characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA (summary of product characteristics). Overview This evidence summary discusses 2 randomised controlled trials (RCTs) looking at the safety and efficacy of fluticasone furoate/umeclidinium/vilanterol (an ICS/LAMA and LABA combination inhaler) in people with COPD who were symptomatic despite regular maintenance treatment and who either had a history, or were at risk, of exacerbations. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 54 Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18) Fluticasone furoate/umeclidinium/vilanterol (Trelegy) is licensed for maintenance treatment of adults with moderate-to severe COPD who are not adequately treated by a combination of an ICS and a LABA. Fluticasone furoate/umeclidinium/vilanterol has been shown to reduce the annual rate of moderate or severe exacerbations by 15% compared with fluticasone furoate/vilanterol.